Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

PURPOSE: In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations....

Descripción completa

Detalles Bibliográficos
Autores principales: Janku, Filip, Abdul Razak, Albiruni R., Chi, Ping, Heinrich, Michael C., von Mehren, Margaret, Jones, Robin L., Ganjoo, Kristen, Trent, Jonathan, Gelderblom, Hans, Somaiah, Neeta, Hu, Simin, Rosen, Oliver, Su, Ying, Ruiz-Soto, Rodrigo, Gordon, Michael, George, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526717/
https://www.ncbi.nlm.nih.gov/pubmed/32804590
http://dx.doi.org/10.1200/JCO.20.00522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526717/
https://www.ncbi.nlm.nih.gov/pubmed/32804590
http://dx.doi.org/10.1200/JCO.20.00522

Ejemplares similares